Pibrentasvir - CAS# 1353900-92-1

Pibrentasvir, CAS No. 1353900-92-1, also known as ABT-530, is a protease inhibitor potentially for the treatment of HCV infection.

Product information

CAS Number: 1353900-92-1

Molecular Weight: 1113.18

Formula: C57H65F5N10O8

Synonym:

ABT530

ABT 530

A 1325912

A1325912

A 1325912.0

A1325912.0

ABT-530

A-1325912

A-1325912.0

Related CAS Number:

1821461-48-6 (butanamine hydrate)

Chemical Name: dimethyl((2S,2'S,3R,3'R)-((2S,2'S)-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-1H-benzo[d]imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methoxy-1-oxobutane-1,2-diyl))dicarbamate

Smiles: C[C@@H](OC)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1NC2=CC(F)=C(C=C2N=1)[C@H]1CC[C@H](C2C=C3N=C(NC3=CC=2F)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)N1C1C=C(F)C(=C(F)C=1)N1CCC(CC1)C1C=CC(F)=CC=1

InChiKey: VJYSBPDEJWLKKJ-NLIMODCCSA-N

InChi: InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

1. Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol. 2019 Jan;14:89-110. doi: 10.2217/fmb-2018-0233. Epub 2018 Nov 30. Review. PubMed PMID: 30499343.
2. Clinical Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533768/ PubMed PMID: 30462453.
3. Pharmacoeconomic Review Report: Glecaprevir / Pibrentasvir (Maviret): (AbbVie Corporation): Indication: Hepatitis C genotype 1 to 6 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK533682/ PubMed PMID: 30462452.
4. CADTH Canadian Drug Expert Committee Recommendation: Glecaprevir / Pibrentasvir (Maviret — Abbvie Corporation): Indication: Chronic hepatitis C virus infection [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533338/ PubMed PMID: 30457786.
5. Glecaprevir/pibrentasvir for hepatitis C. Aust Prescr. 2018 Oct;41(5):169-170. doi: 10.18773/austprescr.2018.050. Epub 2018 Aug 2. Review. PubMed PMID: 30410216; PubMed Central PMCID: PMC6202291.

Products are for research use only. Not for human use.